Actively Recruiting
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Led by LaNova Medicines Limited · Updated on 2026-05-11
400
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.
CONDITIONS
Official Title
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to participate and sign informed consent
- Age 18 years or older, any gender
- Weight at least 40 kg or BMI at least 18.5 kg/m²
- ECOG performance status of 0 or 1
- Life expectancy of at least 3 months
- Histologically or cytologically confirmed locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Confirmed CCR8-positive status by central laboratory
- HER2-negative, low-expressing, or non-expressing tumor
- Experienced disease progression during or after prior standard first-line therapy or intolerance to chemotherapy due to toxicity
- At least one measurable lesion
- Adequate organ and marrow function based on lab tests
- Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 6 months after last dose
You will not qualify if you...
- Received treatment targeting regulatory T cells or the same target molecule
- Received chemotherapy, radiotherapy, biological therapy, immunotherapy, or Chinese herbal medicine within 2-4 weeks prior to first dose
- Received anti-PD-(L)1 antibody immunotherapy with disease progression within 2 months after treatment start
- Used any live vaccine within 4 weeks before first dose
- Had major surgery or interventional treatment within 4 weeks before first dose
- Taken systemic corticosteroids (>10 mg prednisone equivalent) or immunosuppressive drugs within 2 weeks before first dose
- Have unresolved adverse events from prior antitumor therapy above grade 1 or severe immune-related adverse events
- Have any other pathological cancer type
- Have uncontrollable fluid accumulation in the body
- Have unstable or progressing central nervous system metastases or carcinomatous meningitis
- Have a known history of autoimmune disease
- Have drug allergies or contraindications
- Any other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
M
Mengmeng Liu
CONTACT
P
Paul Kong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here